The most common side effects in studies were high blood cholesterol (84% of patients), high blood triglycerides (67%), edema (55%), peripheral neuropathy (48%), cognitive effects (29%), fatigue (28%), weight gain (26%), and mood effects (23%). Serious side effects led to dose reduction in 23% of patients and in termination of<unk>  treatment in 3% of patients.
Lorlatinib
Tucatinib
Neratinib
Fostamatinib
Lapatinib
Ponatinib
Brigatinib
Selpercatinib